There is an urgent need to define mechanisms underlying pancreatic adenocarcinoma (PDA) development. Our studies of ubiquitin ligases that may underlie PDA development led us to identify and characterize RNF125. We show that RNF125 exhibits nuclear expression in acinar cells, with reduced and largely cytosolic expression in ductal cells, PanIN and PDA specimens.
Failure to maintain cellular homeostasis in response to environmental insult such as inflammation or tissue injury, promotes trans-differentiation of acinar cells, known as acinarto ductal metaplasia (ADM), resulting in a ductal cell lineage 10, 11 . Underlying this process is coordinated regulation of transcriptional and epigenetic networks, including changes in SOX9 and hepatocyte nuclear factor 6 (HNF6) expression, both of which function in somatic stem cell reprogramming over the course of pancreatic development [12] [13] [14] . ADM to some extent is reversible if cellular homeostasis is re-established; however, sustained insult, especially when combined with genetic and epigenetic changes, drives an irreversible state in which ductal cells enter a PanIN phase resulting in a pancreatic intraepithelial neoplasm, a critical step in PDA development 12, 14 .
The transcription factor pancreatic and duodenal homeobox 1 (PDX1) is required for differentiation of all pancreatic cell lineages 15 , and PDX1 loss is associated with more aggressive phenotypes of PDA 16 . Another factor implicated in ADM is the nuclear receptor 5A2 (NR5A2), which has been linked with the control of acinar identity and pancreatic inflammation and repair 17, 18 . NR5A2 is more highly expressed in human pancreatic cancer specimens than in normal pancreas and supports proliferation of PDA cell lines 19 .
The ubiquitin system plays a key role in tumor development, progression and resistance mechanisms [20] [21] [22] [23] , and changes in activity of several ubiquitin ligases are reportedly seen in PDA development as well as that of other cancers 21, [24] [25] [26] . In search for ubiquitin ligases (UBLs) that are differentially expressed in pancreatic cancer and normal tissues and potentially linked with PDA prognosis we identified the RING-type E3 ubiquitin ligase RNF125. As a 232 aa protein RNF125
harbors a N-terminal RING domain and two central zinc finger domains. Earlier studies have demonstrated that RNF125 controls RIG-I stability, with concomitant effect on the regulation of T cell activation, and antiviral innate immunity 28, 29 . In pancreatic tissues, we report that RNF125 expression is reduced over the course of acinar-ductal phases and as PDA develops. We identify that RNF125 regulates HDAC2 activity with concomitant effect on the expression of PDX1. Our studies suggest that RNF125-HDAC2-PDX1 axis support early phases in pancreas development, while antagonizes PDA tumor growth,
Results

The ubiquitin ligase RNF125 is differentially expressed in the exocrine pancreas
To identify UBLs that contribute to the etiology of PDA, we queried the TCGA database for UBLs differentially expressed in cancer, including melanoma 27,30 , ovarian cancer 31 , breast cancer 32-34 , colorectal cancer 35, 36 , lung cancer 37 , and head and neck cancer 36, 38 . Of the UBLs that were altered in pancreatic cancer ( Fig S1A) we selected UBLs whose expression may be linked with survival.
Two RING finger ubiquitin ligases that met these criteria, were RNF125 and RNF2. Whereas RNF125 expression negatively correlated with survival, RNF2 expression exhibited an opposite pattern ( Fig. S1A ).
Decreased RNF125 expression was found in 22% of PDA cases; those changes included reduced transcription (28/149) and partial deletion of the RNF125 locus (5/149) on chromosome 18 ( Fig   S1A) . Independent evaluation of RNF125 expression using the TCGA database confirmed that RNF125 downregulation seen PDA is not common in other tumors (i.e. AML, melanoma; Fig.   S1B ). Correspondingly, PDA tumor specimens were found to exhibit lower levels of RNF125
expression, compared to that in surrounding normal pancreas (Fig. S1C ). Given the differences observed for RNF125 in PDA we set to further study its possible importance for this tumor type.
We next assessed potential changes in RNF125 expression between the normal pancreas and PDA. Immunostaining of normal pancreas revealed differential expression and localization of RNF125 in the exocrine pancreas. While acinar cells exhibited relatively increased and mostly nuclear RNF125, the ductal epithelium exhibited lower RNF125 levels, and RNF125 was largely excluded from the nucleus in ductal cells (Fig. S2A ), implying that RNF125 expression and nuclear localization may be important for the maintenance of normal pancreas. To test this possibility, we assessed pancreatic organization in RNF125 knockout (KO) mice ( Figure 1A -B). Notably, smaller pancreata exhibiting decreased expression of developmental (also implicated in acinar) markers (NR5A2, PDX1, GATA6, MIST1; Figure 1C ) versus increased ductal markers (PTF1A, SOX9, FGF10; Figure 1D , 1E) were seen in 6-week-old RNF125 KO relative to WT mice. Along these lines, carboxypeptidase A1, amylase and pancreatic lipase, markers associated with acinar cells and exocrine activity were downregulated in pancreata of RNF125 KO mice (Fig. 1F ). Chromogranin and insulin levels, associated with endocrine activity, were somewhat lower in RNF125 KO pancreata, although plasma glucose levels were not significantly altered, albeit somewhat increased (Fig. 1G) . Correspondingly, pancytokeratin staining revealed increased numbers of ductal structures within the pancreatic parenchyma in RNF125 KO mice (Fig. 1H ). These observations suggest that RNF125 expression is associated with acinar state as part of normal pancreas homeostasis.
Transformed cells exhibit changes in expression and subcellular RNF125 localization
Changes in RNF125 expression and localization noted in acinar vs. ductal cells (Fig S2A) prompted us to determine the level and localization of RNF125 in a cohort of human PDA samples. While in a few cases (4/22) RNF125 expression was high and detectable in the nucleus, most tumor samples (18/22) exhibited relatively low expression of RNF125 that was largely cytosolic (Fig. S2B ). RNF125 expression was also reduced in cancer-associated fibroblasts surrounding tumor islets (Fig. S2B) . Notably, higher RNF125 protein levels were associated with improved prognosis (Fig. S2B , Table 1 ). To confirm these observations, we analyzed a TMA consisting of 84 PDA cases. Of those, 32% exhibited low RNF125 levels, 58% were RNF125-negative, and only 10% exhibited strong RNF125 staining, of which only 2 were nuclear (Fig. S2C) . Notably, low levels of RNF125 expression coincided with a poorer differentiation grade (Fig. S2C , Table 2 ). Moreover, lower RNF125 levels in this context were also observed in 8 out of 10 PDA cell lines (Fig. S2D ). Overall, decreased nuclear RNF125 was identified in human pancreatic ductal epithelium cells, compared to the mostly acinar normal pancreas, with further decrease in nuclear RNF125 seen in human PDA cell lines (Fig. S2E) .
To further assess possible changes in RNF125 expression in tumor development, we monitored RNF125 expression in human pancreatic intraepithelial neoplasm (PanIN), the early precursor of a malignant PDA lesion. Lower levels of RNF125 protein as well as relatively decreased nuclear expression was detected in PanIN samples compared with surrounding acinar cells ( Fig.   S2F ), suggesting that altered expression (lower level and nuclear exclusion) of RNF125 may be linked with PDA development.
To directly assess possible importance of RNF125 in PDA, we assessed the expression and (Fig. S3A, C) . These data suggest that RNF125 requires its ubiquitin ligase function to exert a tumor growth inhibitory function.
Inoculation of KPC-driven organoids stably expressing shRNF125 resulted in larger PDA tumors and a corresponding decrease in mouse survival ( Fig. 2B-C) . Immunohistochemistry of KPC tumors subjected to RNF125 knockdown revealed increased proliferation, reflected in elevated level of Ki67 expression (Fig. 2D ) which was accompanied by elevated alpha smooth muscle actin (αSMA) expression, coupled with increased trichrome staining of collagen, indicative of enhanced fibroblast and desmoplastic involvement (Fig. 2D, 2E ). Additionally, inhibition of RNF125 expression reduced the number of malignant ductal structures observed by CK19 staining, indicative of dedifferentiation (Fig. 2D, 2F ) and lower level of cleaved caspase 3 (Fig. 2G) , reflective of reduced apoptosis. Notably, shRNF125-expressing tumors showed increased expression of EMT markers (Fig. 2H) , consistent with appearance of dedifferentiation phenotypes (Fig. 2D, 2F ). KPC tumors expressing shRNF125 did not exhibit changes either T cell infiltration or angiogenesis, reflected by unaltered level of CD45 + , CD8 + , and CD31 + expression (Fig. S4A) . Overall, these observations suggest that RNF125 limits PDA growth.
Given the importance of desmoplastic stroma in PDA development, we monitored possible changes in the expression of stromal markers in tumors subjected to RNF125 KD, compared with WT controls. Among fibrogenesis markers, PDGFRα was significantly increased while TGF-β2, TGF-β3, and TNF-a expression were consistently and significantly lower in RNF125 knockdown KPC tumors (Fig. S4B) . Noteworthy, the growth of orthotopically implanted KPC tumors in RNF125 KO and WT mice was comparable, and there were no changes in fibroblast activation or tumor grade between genotypes ( Fig. S4C-D) . These findings suggest that RNF125 contribution to PDA development primarily occurs through its tumor intrinsic effects.
RNF125 controls PDA growth via differential regulation of PDX1
In light of the changes in RNF125 expression and subcellular localization seen in acinar and ductal pancreatic cells, we asked whether genes implicated in pancreatic lineage differentiation or regeneration may be regulated by RNF125 in PDA. Among genes that were implicated in lineage differentiation and development in the pancreas are the transcription factors PDX1, MNX1, and NR5A2 9 . Indeed, a number of markers of acinar activity, including PDX1 and NR5A2, were upregulated in RNF125 High PDA (Fig. 3A) . Since NR5A2 and PDX1 function in pancreatic acinar differentiation and are reportedly linked to PDA initiation and growth 19,40 , we asked whether RNF125 is involved in their regulation also in PDA. RNF125 expression was associated with the expression of both PDX1 and NR5A2 in normal pancreas (Fig. 1D) , and inhibition of RNF125 resulted in a lower PDX1 and NR5A2 expression in KPC organoids (Fig.   3B ), human PDA cell lines (Fig. S5A ) and KPC tumors (Fig. 3C) . However, the expression of PDX1, but not NR5A2 was upregulated in RNF125 High compared with RNF125 Low human PDA (Fig. 3D ). These observations suggest that RNF125 expression controls PDX1 but not NR5A2 expression in human PDA, which led us to further focused on the PDX1-RNF125 regulatory axis. Indeed, ectopic expression of WT, but not RING mutant (RM), form of RNF125 restored PDX1 expression, suggesting that for its control of PDX1 transcription RNF125 requires its ubiquitin ligase function ( Fig 3E) . Notably, analysis of a large patient cohort consisting of four different pancreatic cancer subtypes, low expression of RNF125 and PDX1 was seen in squamous type PDA, which is associated with low survival 16 (Fig. 3F ).
To further assess the status of RNF125 and PDX1 in PDA, we monitored changes in the expression of these proteins at different stages of pancreatic cancer development in human samples. The level of PDX1 expression was somewhat lower in PanIN and PDA compared with the normal pancreas ( Fig 3G) . Likewise, PanIN from the pancreas of the KPC mice exhibited limited changes in PDX1 expression (Fig. 3H ). These observations point to direct correlation between PDX1 and RNF125 expression.
Analysis of PDA patient specimens in the TCGA dataset revealed that high PDX1 expression is associated with prolonged survival (Fig. 3I) . Notably, tumors expressing both RNF125 and PDX1 showed better survival, compared with tumors expressing low PDX1 or low PDX1/RNF125 (Fig. S5B, S5C) To assess the potential effect of RNF5-PDX1 expression on PDA we asked whether PDX1 mediates RNF125 effects. On its own, altered PDX1 expression elicited a notable effect on pancreatic tumor growth based on analysis of 2D growth of PDA cell lines ( Fig. S5D and organoids (Fig. 4A) . Notably, while inhibition of PDX1 expression using siRNA did not led to a marked increase in PDA cell line proliferation, ectopic expression of PDX1 was able to significantly inhibit PDA cell proliferation (Figs. 4A, S5D ). We then injected KPC organoids orthotopically into syngeneic C57BL/6 mice and monitored the formation of pancreatic tumors ( Fig 4B) . As expected, inhibition of RNF125 expression in organoids further accelerated tumor growth in vivo. Notably, overexpression of PDX1, attenuated the enhanced growth seen in RNF125 knockdown organoids and resulted in smaller tumors that exhibited decreased proliferation, and increased apoptosis (Fig. 4C) . Notably, loss of PDX1 in MiaPaCa-2 cells, increased epithelial to mesenchymal transition (EMT), which was monitored using N-Cadherin and Vimentin as markers (Fig. S5E) . Consistent with these observations, overexpression of PDX1 reverted the increased EMT, seen upon RNF125 KD (Fig. S5F ). These findings substantiate the importance of RNF125 and PDX1 in PDA development/progression.
Nuclear RNF125 interacts with histone deacetylase 2 to decrease its repressive function and attenuate tumor growth
As a ubiquitin ligase, RNF125 should limit either stability or activity of its putative substrates.
Yet, given that RNF125 altered PDX1 mRNA levels (Fig S5A) , we sought to identify a regulatory protein intermediate as a potential RNF125 substrate. To do so, we performed massspectroscopy (MS) using RNF125 as bait, which led us to identify both nuclear and cytosolic RNF125-interacting proteins, some previously reported to play a role in PDA ( Fig 5A , Table   S1 ). Given that nuclear RNF125 expression is more prominent in nuclei of non-transformed cells and that PDX1 transcription was linked with RNF125 activities, we searched for putative substrates that govern gene transcription, and thus focused on nuclear RNF125-interacting proteins. Our criteria for selection of substrates included: (i) the ability of an RNF125 substrate to alter transcription of PDX1, and (ii) inhibition of the substrate should rescue phenotypes seen following RNF125 inhibition. When we tested the nuclear RNF125-interacting proteins based on these criteria, only HDAC2 inhibition effectively restored the level of PDX1 expression, which were inhibited upon RNF125 knockdown (Fig. 5B) . Immunoprecipitation (IP) of ectopically expressed RNF125 in the MiaPaCa-2 cell line confirmed HDAC2 interaction (Fig.   5C ), and further subcellular fractionation analysis of endogenous proteins showed that interaction was also detected in the nucleus ( Fig. 5D-E) . Notably, the degree of RNF125/HDAC2 interaction and HDAC2 levels were unaltered upon treatment of cells with proteasome inhibitors (Fig. 5D ), suggesting that RNF125 does not alter HDAC2 stability.
Indeed, levels of HDAC2 protein in pancreas were comparable in RNF125 WT and KO mice (Fig. 5F ). Likewise, both WT and RNF125 knockdown KPC tumors exhibited similar HDAC2 levels ( Fig. 5G) . Furthermore, human PDA specimens expressing high RNF125 levels exhibited levels of HDAC2 comparable to specimens expressing low RNF125 levels (Fig. 5H) . Lastly, inhibition of RNF125 expression in PDA cell lines did not alter basal levels or half-life of HDAC2 ( Fig. S6A-B) . Collectively, these observations suggest that RNF125 does not affect HDAC2 stability.
Next, we assessed potential effects of RNF125 on HDAC2 ubiquitination. Indeed, inhibition of RNF125 expression in HEK293T cells over-expressing HDAC2 decreased levels of ubiquitin chains of the K63-topology on HDAC2, as compared to WT controls (Fig. 5I) . Conversely, ectopic RNF125 expression increased the level of HDAC2 K63-linked ubiquitinated HDAC2
relative to controls, whereas overexpression of the RNF125 RING mutant inhibited HDAC2
non-canonical ubiquitination (Fig. 5I) . Likewise, RNF125 inhibition reduced the degree of endogenous HDAC2 K63-linked ubiquitination in both the human MiaPaCa-2 and mouse KPC cells ( Fig. S6C-D) , while no changes were detected in the levels of HDAC2 K48-ubiquitination (Fig. S6E ). Expression of a K63R mutant form of ubiquitin, which should selectively block K63-linked ubiquitin chain, decreased the degree of RNF125-dependent HDAC2 ubiquitination (Fig. S6F ).
Given that HDAC2 reportedly represses transcription 41 , and since HDAC2 was subjected to K63 ubiquitination, we assessed effects of HDAC2 on PDX1 expression. Inhibition of HDAC2 expression with shRNA in KPC organoids led to increased PDX1 expression, which was unchanged following RNF125 inhibition (Fig. 6A) . Similarly, HDAC2 knockdown in human PDA cells also increased PDX1 protein levels concomitant with increased histone H3K27 acetylation ( Fig. S7A ). Chromatin IP analysis also revealed enrichment of HDAC2 on the PDX1
promoter, which coincided with lower levels of H3K9ac and H3K27ac on PDX1 promoter ( Our studies further demonstrate that RNF125 indirectly regulates expression of the PDAassociated transcription factor PDX1. Evidence supporting the importance of RNF125 and its regulation of PDX1 for PDA development comes from our rescue studies showing that PDX1 overexpression restores phenotypes seen upon RNF125 knockdown, both in organoids and in orthotopic tumor models.
Notably, our studies identified HDAC2 as an RNF125 substrate, and suggest that HDAC2 activity is regulated by RNF125-mediated K63-linked ubiquitination. Ubiquitination by RNF125 altered HDAC2 activity, as reflected by histone acetylation of the PDX1 promoter region, an activity that may have also been impacted by reduced HDAC2 recruitment to that promoter. Notably, we confirmed a link between HDAC2 and PDX1 in series of studies performed in both KPC organoids and in orthotopic tumor xenografts, in which HDAC2
inhibition rescued growth phenotypes observed following RNF125 inhibition. RNF125 control of HDAC2 activity likely regulates transcription of genes other than PDX1, consistent with our finding of altered transcription of other pancreatic differentiation factors in RNF125 KO mice.
Accordingly, better prognosis seen in patients whose PDA specimens harbor elevated RNF125
and HDAC2 expression suggests that components of a transcriptional network along this regulatory axis could serve as markers for PDA development and in stratifying patients for treatment with HDACi.
Relatively lower RNF125 levels were observed in PDA compared to healthy tissues, as was an inverse correlation between RNF125 expression and differentiation grade of human tumors and patient survival. Correspondingly, reducing RNF125 expression increased tumor growth, a phenotype significantly attenuated after either PDX1 overexpression or, more effectively, HDAC2 knockdown. Thus, our work reveals a mechanism controlling PDX1 suppression by
HDACs, that may underlie dedifferentiation and cell transformation. Would HDACi offer a novel therapeutic modality for PDA? Our findings support such a possibility, which should be further confirmed experimentally. For one, potential use of domatinostat, a class I HDAC inhibitor, which is currently being evaluated against microsatellite stable colorectal cancer in clinical trials (NCT03812796), could also be evaluated in RNF125 low-expressing PDAs.
In summary, our data suggest that HDAC2 inhibition by RNF125 plays a critical role in maintaining acinar differentiation in the exocrine pancreas. We conclude that RNF125 deregulation is important driver of pancreatic transformation, through its control of HDAC2 activity and transcriptional regulation of key factors in PDA, including PDX1.
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(to ZR) and NCI grant R35CA197465 (to ZR Organoid culture. Organoids were prepared as described 43 . Briefly, bulk orthotopic KPC tumors were minced and digested overnight with collagenase XI and dispase, washed, counted, embedded in growth factor-reduced (GFR) matrigel (Corning, 1 x 10 5 cells suspended in a 50μl matrigel dome), and cultured in murine complete medium [Advanced DMEM/F12 medium supplemented with HEPES (1x, Corning), Glutamax (1x, Gibco), penicillin/streptomycin (1x, Gibco), B27 (1x, Invitrogen), N-acetyl-L-cystenine (1mM, Sigma), A83-01 (500 nM, Sigma), RSPO-1 conditioned medium (10% v/v, Cultrex® Rspo1 produced by HEK293T cells, Trevigen), mNoggin (0.1 μg/ml, Peprotech), mouse epidermal growth factor (mEGF, 50 ng/ml), Gastrin-I (10nM, Peprotech), human fibroblast growth factor 10 (hFGF10, 100 nm/ml, Peprotech), and nicotinamide (10 mM, Sigma)]. To isolate protein or RNA, or for orthotopic injection of organoids, matrigel was manually disrupted in cold PBS at indicated time points, and organoids were washed and collected. For organoid immunofluorescence and immunohistochemistry, the matrigel dome was fixed in formalin, embedded and cut.
Cycloheximide chase assay. Cycloheximide chase was performed as previously described 44 .
Briefly, cycloheximide (50 μg/ml) was added to cells for indicated times, and cell lysates were analyzed with indicated antibodies.
Cell viability assay in 2D culture. Cell growth was assayed using the standard trypan blue exclusion assay or ATPlite (Perkin Elmer). Briefly, 4 hours after transfection, PDA cells were washed, harvested, and cultured in 96-well plates with a transparent bottom (5,000 cells/well).
For paclitaxel treatment, drug was added 24 hours after seeding, and then cells were incubated 48 hours. Cell growth or viability was measured using ATPlite, and results were quantified by monitoring luminescence intensity or examining trypan blue incorporation using automated cell counter (Countess II FL, Life Technologies).
Colony-forming and sphere-forming assays. For colony-forming assays, 500 or 1,000 PDA cells were seeded in a 6-well plate, and wells were monitored daily by microscopy for colony formation. After 10 days, colonies were visualized by crystal violet staining (Sigma). Colony number was analyzed using ImageJ software (NIH). For spheroids formation, 24 hours after Immunofluorescence. After deparaffinization and antigen retrieval, slides were washed in water followed by PBS, incubated in 0.05% Tween for 15 minutes, and blocked in 10% goat serum (1 hr at room temperature). Slides were then incubated with diluted primary antibody RT-qPCR analysis. RNA was extracted from cell lines and homogenized tumors using a GenElute Mammalian Total RNA Purification Kit (Sigma) according to standard protocols. RNA concentration was measured using a NanoDrop spectrophotometer (ThermoFisher). cDNA was synthesized from aliquots of 1μg total RNA using a high-capacity cDNA synthesis kit (Applied Biosystems). Quantitative PCR was performed with SYBR Green I dye master mix (BioRad) and a CFX connect Real-Time PCR System (Bio-Rad). Primer sequences are listed in Table S1 . Primer efficiency was measured in preliminary experiments, and amplification specificity was confirmed by dissociation curve analysis.
Mass spectrometry. Mia PaCa-2 cells were transfected with control plasmid (pcDNA3.0 with a FLAG-tagged C terminus) or plasmid encoding FLAG-tagged RNF125RM. Cells were lysed 24 hr after transfection using 1% Triton-lysis buffer (50 mM Tris-HCl [pH 7.4]) and 150 mM NaCl, 1 mM EDTA, 1% [v/v] Triton X-100, a protease inhibitor cocktail (Phostop, Roche) and pre-cleared with protein A/G agarose beads (Santa Cruz). IP was performed using FLAG-M2-agarose beads (Sigma). Beads were then resuspended with 8M urea, 50 mM ammonium bicarbonate, and processed for LC-MS/MS analysis using a nanoACQUITY system (Waters) coupled to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific) as previously described 45 . All mass spectra were analyzed with MaxQuant software version 1.5.5.1. MS/MS spectra were searched against the Homo sapiens Uniprot protein sequence database (version January 2018) and GPM cRAP sequences (commonly known protein contaminants). Post-search data analysis was performed with R-64 bit version 3.5.1, including the R Bioconductor packages such as limma and MSstats. Statistical significance was calculated using two-way ANOVA. 
Chromatin immunoprecipitation assay (ChIP). KPC cells (4 x 10
